Ventures

Surfacto BioTec is developing innovative life science tools based on bacterial surface proteins.

No description available

Insilico Medicine

Insilico Medicine is a biotechnology company focused on leveraging generative artificial intelligence (AI) and automation for drug discovery and development. The company aims to accelerate and improve the process of discovering and developing novel therapeutics, with a focus on longevity and sustainability.

LoopLab Bio GmbH

Germany

LoopLab is an emerging biotech company developing a first-in-class Fc-Engager platform to induce antigen-specific immune tolerance. Our lead program, LL-HDM, targets house dust mite (HDM) allergy – a major cause of perennial allergic rhinitis and asthma – with a short-course biologic designed to “re-educate” the immune system rather than just suppress symptoms. By fusing disease-specific antigens to an engineered inhibitory Fc domain, our Fc-Engagers selectively silence pathogenic B cells and promote regulatory pathways, aiming for durable remission with minimal systemic immunosuppression. The same modular platform can be rapidly adapted to autoimmune diseases (e.g. celiac disease, bullous pemphigoid) and to prevent anti-drug antibodies against biologics. We are currently in late preclinical development for LL-HDM, supported by €9.6M in seed funding and €1.5M in grants, and preparing a Series A financing of €30–50M in 2026 to reach IND (2027) and First-in-Human (2028). LoopLab is led by a seasoned team with deep experience in immunotherapy, CMC, and clinical development from MSD, Themis, Valneva, Evotec, and others, complemented by an advisory board with strong pharma partnering and clinical trial expertise. Our strategy is to achieve early clinical proof-of-concept in HDM allergy, then monetize via out-licensing and platform partnerships while expanding into high-value autoimmune indications.

Utilizer AB

Saltsjö Boo, Sweden

Company Overview Utilizer is a MedTech start-up from KTH Royal Institute of Technology, focused on Point-of-Care (POC) diagnostics for bacterial infections. Our mission: - Responsible use of Antibiotics - Save healthcare costs - Improve patient outcomes Solution – First product for market for Urinary Tract Infections, Utilizer®-ID - Miniaturized culture-based diagnostic tool for UTIs at POC - Gold-standard accuracy, results in hours, analyzed via smartphone in 10 seconds - No lab equipment investment - Covers >95% of UTI pathogens - Patent granted in US, pending EU Clinical Validation - Trials at Karolinska: 96% sensitivity, 87% specificity - Usability study at 4 POC sites showing ease of use and fit in current POC workflow with 100% users recommending it for others - IVDR certification in progress Next product in pipeline, Utilizer AST bacterial resistance testing Exit strategy Diagnostic or microbiology company (Roche Diagnostics, Thermo Scientific, Abbott, Biomérieux, Siemens) within 5 years

ReMinded, Inc.

Boston, United States

ReMinded, Inc. is a MedTech startup on a mission to become the leading solution in salivary diagnostics. Currently, the team is commercializing the first clinical-grade, rapid saliva test that tracks cortisol(a key stress hormone)on demand, unlocking a vital biomarker for psychiatry and behavioral health. The system syncs seamlessly to a desktop platform, enabling clinicians and patients to monitor stress in real-time, reducing reliance on solely subjective assessments for e.g addiction treatment decisions and PTSD.

LipoNexus Diagnostics

San Diego, United States of America

LipoNexus is commercializing the first highly accurate, non-invasive blood test for early detection of Metabolic Associated Steatotic Liver Disease (MASLD).

AOA Dx

United States of America

AOA Dx is closing the gap with AKRIVIS GD, a first-of-its-kind multi-omic blood test for ovarian cancer detection in symptomatic women.

sefit health AG

Switzerland

sefit develops a clinically guided VR-based digital therapeutic designed to support individuals with autism, ADHD and migraine in managing sensory overload.

Brnlit.AI GmbH

Basel, Switzerland

BRNLIT.AI offers a personalised, non-pharmacological digital therapeutic using EEG-based light-stimulation to improve focus and attention regulation.

mTatt

Canada

mTatt is a medtech startup developing functional microtattoos for real-time, at-home health monitoring using dissolving microneedles.

Long-term organ perfusion as a preclinical platform for drug testing.

Nimble Science

Canada

Nimble Science is transforming gastrointestinal health with the SIMBA Capsule - a swallowable, single-use device that safely collects endoscopic-quality fluid samples from the small intestine.

SURFACtoBioTech GmbH

Germany

SURFACtoBioTech is building the first full‑stack droplet experimentation platform that unites proprietary surfactant chemistry, automated hardware and AI‑enabled analytics into one ecosystem. Our technology converts microliter‑scale samples into 100,000 uniform picoliter droplets from just 10 µL, generating orders of magnitude more high‑quality data at dramatically lower cost and turnaround time. Installed as modular instruments with integrated consumables and software, our platform enables academic, diagnostic and pharma customers to perform high‑throughput assays, structural biology experiments and screening workflows that are currently too slow, expensive or manpower‑intensive. With two patent families covering surfactant chemistry and system integration, >90% blended gross margins and three recurring revenue streams (platform, consumables, software), SURFACtoBioTech is positioned to become the category‑defining infrastructure provider in droplet microfluidics.

SeeQ Diagnostics

SeeQ develops rapid metagenomics-based precision diagnostics for any clinically relevant pathogen from less than 1 mL blood in 6-8 hours. This approach enables faster, more targeted antimicrobial treatment, for better patient outcomes with reduced adverse events and improved quality of life. In turn, health care usage is reduced through shorter hospital stays, lowered readmittance rates and improved antimicrobial stewardship. Our first product, SepSeeQ, has been evaluated into two prospective clinical trials in an acute care setting and chronic infections related to vascular grafts, with additional two studies ongoing in neonatal sepsis and hematological cancers.

We provide a validated pulsatile endovascular aortic training simulator that has already been used in pilot courses both in the angio suite and in dry-lab settings. In a second step, we are developing complementary high-fidelity 3D-printed open vascular models so that the same training center can cover both endovascular and open vascular procedures in a structured 1–2 day course format.

Synagen

Synagen builds oncology-specific AI agents that automate tumor-board decisions, guideline-based treatment suggestions, and clinical-trial matching, giving every cancer patient access to expert-level care at every visit. We integrate deeply into hospital workflows, reduce documentation and preparation time, and continuously generate structured precision-oncology data that improves outcomes and enables large-scale research over time.

Elyvia Biomedics GmbH

Germany

We convert traditional lateral flow tests into quantitative, lab-grade diagnostic using one drop of blood, enabling both early detection and treatment monitoring. Our proprietary platform combines three core core innovations (1) biosensor test design, (2) AI-driven image analysis and (3) a machine learning-based quantification algorithm. Together, they deliver high-accuracy biomarker measurement in a simple, scalable, self-calibrating and device agnostic format. Our initial focus is ovarian cancer. By integrating multiple biomarkers with patient data such as age, our test outperforms the current CA125 blood test and achieves accuracy comparable to the costly transvaginal-plus-blood testing workflow.

The MAP-AD is the first and only CE-IVDR-marked prognostic solution designed to predict the progression to Alzheimer’s dementia (AD) in individuals with early memory complaints. The device combines Next-Generation Sequencing of mitochondrial DNA biomarkers with artificial intelligence to analyze disease etiology, cognition, and risk factors. This holistic technology identifies patients who will progress to AD dementia years in advance, even before positive amyloid pathology appears. By shifting healthcare from a late, reactive diagnostic model to an early, precise prognosis, MAP-AD enables clinicians to implement pharmacological therapies or preventive lifestyle interventions before irreversible neurological damage. Uniquely differentiated from the market, MAP-AD offers a distinct value proposition: while diagnostic blood tests (e.g., Lumipulse) detect current amyloid presence, MAP-AD forecasts future cognitive decline. This is critical, as amyloid tests often yield false positives regarding actual dementia progression. MAP-AD prioritizes high sensitivity to ensure at-risk patients are not missed and operates independently of amyloid status. Operationally superior, it analyzes whole blood, eliminating the immediate processing required by plasma-based competitors, reducing indeterminate results, facilitating personalized and precision medicine, and patient stratification.

Hormo is an integrated, at-home point-of-care (POC) system designed to address the global diagnostic gap in Polycystic Ovary Syndrome (PCOS), a condition affecting 6–13% of women of reproductive age worldwide. By combining a disposable microfluidic biosensor with a portable reader and mobile app, Hormo enables the quantitative, lab-grade detection of three key hormones—LH, Testosterone, and AMH—from a single finger-prick blood drop .This affordable solution empowers women to perform longitudinal monitoring, facilitating early screening and proactive lifestyle management of hormonal imbalances

AI will transform healthcare, but it will not fix the fundamentals: fragmented care, incompatible data, and the absence of trust. Today no one can reliably prove who did what, or whether the work met the standard or created value. Payers carry the risk, providers fight denials, and value-based care cannot scale because multi-party execution cannot be verified. Adino solves this by treating healthcare like an economic system, not a billing system. We provide cryptographic, operational proof that every party completed their part of a care process. This speeds reimbursement, collapses administrative waste, prevents fraud, and makes outcomes traceable. With Adino, payment can be triggered by proof, not trust. We will become the neutral network that moves healthcare value the way Visa moves money, all without ever needing to see the underlying data. We cannot change human nature, so we’re building a system that doesn’t rely on it.

BugSense develops a paper-based test for simultaneous infection and resistance detection with a softwarebased readout for point-of-care applications.

MSInsight

Paris, Italy

MSInsight develops advanced AI-driven genomic diagnostics to improve cancer treatment selection and early detection of hereditary cancer syndromes. Our core technology, MSIcare, uses next-generation sequencing and proprietary algorithms to detect microsatellite instability (MSI) with higher precision and consistency than traditional workflows. MSI is a critical tumor-agnostic biomarker used to guide immunotherapy eligibility, prognosis, and therapeutic decisions in colorectal, gastric, endometrial, and other solid tumors. MSI also serves as a key molecular signature for identifying hereditary cancer syndromes driven by mismatch repair deficiency, enabling earlier risk detection and adapted surveillance.

KARDI AI Technologies s.r.o

Olomouc, Czech Republic

Kardi Ai is saving lives with AI. We use long-term heart monitoring and artificial intelligence to detect hidden heart rhythm disorders that traditional methods often miss. While standard one-day monitoring detects arrhythmias in roughly 5% of cases, Kardi Ai increases the detection rate to nearly 30% through continuous, long-term monitoring. Our solution gives people an easy way to monitor their heart at home and provides doctors with clear, clinically relevant data — faster diagnosis, better decisions. 300+ lives already saved. Kardi Ai turns prevention into measurable impact.